Schmidt Carsten, Grunert Philip C, Stallmach Andreas
Medizinische Klinik II, Klinikum Fulda AG, Universitätsmedizin Marburg - Campus Fulda, Fulda, Germany.
Klinik für Innere Medizin IV, Universitätsklinikum Jena, Friedrich-Schiller Universität Jena, Jena, Germany.
Front Pharmacol. 2021 Apr 12;12:655054. doi: 10.3389/fphar.2021.655054. eCollection 2021.
The introduction of anti-tumor necrosis factor antibodies resulted in a considerable expansion of the options available for the treatment of inflammatory bowel disease. Unfortunately, approximately one third of treated patients do not respond to these modalities, and drug efficacy may be lost over time. These drugs are also associated with contraindications, adverse events, and intolerance. As such, there is an ongoing need for new therapeutic strategies. Despite several recent advances, including antibodies against pro-inflammatory cytokines and cell adhesion molecules, Janus kinase inhibitors, and modulators of sphingosine-1-phosphate receptors, not all problems associated with IBD have been solved. In this manuscript, we review the current state of development of several new treatment options. Ongoing evaluation will require specific proof of efficacy as well as direct comparisons with established treatments. Results from head-to-head comparisons are needed to provide clinicians with critical information on how to formulate effective therapeutic approaches for each patient.
抗肿瘤坏死因子抗体的引入极大地扩展了炎性肠病的治疗选择。不幸的是，约三分之一接受治疗的患者对这些治疗方式无反应，且药物疗效可能会随时间丧失。这些药物还存在禁忌证、不良事件和不耐受情况。因此，持续需要新的治疗策略。尽管近期有多项进展，包括针对促炎细胞因子和细胞黏附分子的抗体、Janus激酶抑制剂以及鞘氨醇-1-磷酸受体调节剂，但与炎性肠病相关的所有问题尚未得到解决。在本手稿中，我们综述了几种新治疗选择的当前研发状况。持续评估将需要疗效的具体证据以及与现有治疗方法的直接比较。需要进行直接对比的结果，以便为临床医生提供关于如何为每位患者制定有效治疗方法的关键信息。
